Bedel Financial Consulting’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bedel Financial Consulting’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1	Closed	–	–	861
2020 Q1	$0	Buy	+1	New	+$129	﹤0.01%	863

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bedel Financial Consulting's JAZZ Position: Q2 2020 in Review

Bedel Financial Consulting sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2020, closing a stake of 1 share.

Bedel Financial Consulting first reported a position in JAZZ in Q1 2020 and held it in 1 quarter. The position peaked at $0 in Q1 2020. 384 funds tracked by Wall St. Rank hold JAZZ as of Q2 2020.

Bedel Financial Consulting reported no remaining Jazz Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Bedel Financial Consulting sold 1 Jazz Pharmaceuticals share in Q2 2020.
Bedel Financial Consulting first reported a position in Jazz Pharmaceuticals in Q1 2020 and held it in 1 quarter.
Bedel Financial Consulting's Jazz Pharmaceuticals position peaked at $0 in Q1 2020.
384 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2020.

Based on Bedel Financial Consulting's 13F filing for Q2 2020, filed 14 Jul 2020.